NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Fine, my memory focused on the 10.50 buyout price, but my point remains, some companies aren’t squishing little startups and are willing to pay what a company is worth (in that case a 5x premium), and that is not always equivalent to anything near its beaten down stock price.

You can do the math if DCVax-l gets approved as SOC in Gliomas and then all solid tumors. That’s called future valuation. It’s not hard to do, and no one looks at current PPS to arrive at that.

What smart companies do is realize their strengths and weaknesses. NWBO’s weakness is future gauntlet after gauntlet risk with a small contractor based company, BP’s weakness is it keeps failing and making people sick with toxic potions.

NWBO’s strength is it has a powerful platform that initially still includes the need for the oncology surgical community (non threatening) it is safer than anything out there, it has observable immune system method of action with biological markers, and it clearly can be enhanced with combinations. BP’s strength is the ability to acquire (sometimes)great therapies and get them to the global public much faster than small companies can, and absorb the risk whether they partner, buyout or merge the smaller company as a wholly owned subsidiary.